Skip to content
Clinical Trials – home

Find therapies in clinical trials near you – page 58

recruiting
3 968
countries
28
conditions
2 103

835 trials match your criteria

Study of Osimertinib and Chemotherapy for Patients with EGFR Mutation Positive Resectable Non-Small Cell Lung Cancer

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

COVID-19

Not recruiting

Study on the Safety and Effectiveness of Nirmatrelvir and Ritonavir for Nonhospitalized Children with COVID-19 at Risk of Severe Illness

InvestigationalNo placebo
Countries:BulgariaBulgaria
  • Participants:0–17 years
  • Substances:Nirmatrelvir

Breast cancer

Not recruiting

Study on Home Administration of Pertuzumab and Trastuzumab for Patients with Early or Locally Advanced HER2-Positive Breast Cancer

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Pertuzumab

Lupus nephritis

Not recruiting

Study on Anifrolumab for Adults with Active Lupus Nephritis

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Anifrolumab

Study on the Safety and Effectiveness of Betula Pollen Extract for Children and Adolescents Aged 5-17 with Birch Pollen Allergies and Possible Asthma

Registered drug
Countries:BulgariaBulgaria
  • Participants:0–17 years
  • Substances:Betula Pollen Extract

Study on the Effectiveness and Safety of OCS-01 Eye Drops with Dexamethasone for Patients with Diabetic Macular Edema

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
Countries:BulgariaBulgaria
  • Participants:18–64 years
  • Substances:Golimumab

Colitis ulcerative

Not recruiting

Study on the Effects of Guselkumab and Golimumab for Patients with Moderate to Severe Ulcerative Colitis

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years
  • Substances:Golimumab

Cognitive disorder+1

Not recruiting

Study on RL-007 for Improving Cognitive Impairment in Schizophrenia Patients

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years
  • Substances:(2R,3S)-2-Amino-3-Hydroxy-3-Pyridin-4-Yl-1-Pyrrolidin-1-Ylpropan-1-One (2R,3R)-2,3-Dihydroxybutanedioic Acid

Study Comparing Pirtobrutinib to Bendamustine and Rituximab for Untreated Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Pirtobrutinib

Myelofibrosis+1

Not recruiting

Study on the Safety and Effects of Navitoclax and Ruxolitinib for Patients with Myelofibrosis and Myeloproliferative Neoplasms

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Celecoxib

Study of Encorafenib, Binimetinib, and Pembrolizumab for Patients with Advanced Melanoma with BRAF V600E/K Mutation

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Binimetinib
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.